Table 2.
Dicarbonyl and AGE levels in the plasma and spinal cord after daily oral vehicle or pyridoxamine (10 g/L) treatment during EAE.
| Substrate | Product | Vehicle n = 11 | Pyridoxamine n = 10 | p-Value |
|---|---|---|---|---|
| Plasma | ||||
| MGO (nmol/L) | 2270 ± 208 | 2488 ± 227 | 0.49 | |
| GO (nmol/L) | 1447 ± 159 | 1391 ± 91 | 0.77 | |
| 3DG (nmol/L) | 1496 ± 89 | 1642 ± 44 | 0.17 | |
| Protein bound CML (nmol/mmol Lysine) | 19.7 ± 1 | 20 ± 2 | 0.89 | |
| Protein bound CEL (nmol/mmol Lysine) | 5.3 ± 0.4 | 4.7 ± 0.4 | 0.31 | |
| Protein bound MG-H1 (nmol/mmol Lysine) | 217.0 ± 12 | 239.2 ± 15 | 0.25 | |
| Free CML (nmol/L) | 364.5 ± 137 | 218.4 ± 10 | 0.32 | |
| Free CEL (nmol/L) | 138.8 ± 70 | 71.6 ± 6 | 0.37 | |
| Free MG-H1 (nmol/L) | 96.6 ± 37 | 63.6 ± 7 | 0.42 | |
| Spinal cord | ||||
| MGO (nmol/L) | 1976 ± 177 | 1977 ± 132 | 1.00 | |
| GO (nmol/L) | 2117 ± 122 | 2207 ± 150 | 0.65 | |
| Protein bound CML (nmol/mmol Lysine) | 97.6 ± 12 | 95.9 ± 12 | 0.92 | |
| Protein bound CEL (nmol/mmol Lysine) | 50.2 ± 4 | 52.2 ± 5 | 0.75 | |
| Protein bound MG-H1 (nmol/mmol Lysine) | 108.3 ± 11 | 132.1 ± 17 | 0.25 | |
| Free CML (nmol/L) | 92.9 ± 5 | 97.3 ± 5 | 0.56 | |
| Free CEL (nmol/L) | 17.6 ± 0.4 | 17.9 ± 0.5 | 0.59 | |
| Free MG-H1 (nmol/L) | 4.5 ± 0.2 | 4.8 ± 0.3 | 0.43 | |
| Glo-1 activity (nmol/mg/min) | 1614 ± 46 | 1572 ± 59 | 0.58 |
Data presented as mean ± SEM and analyzed using unpaired t-test.